Early Treatment Key to Treat Hepatitis C
Posted on: Tuesday, 12 August 2008, 18:00 CDT
Canadian researchers say patients who receive early treatment for hepatitis C within the first months following an infection, develop a rapid immune response.
The study, published in the Journal of Virology, said that early treatment can restore immune response against hepatitis C and help eliminate the virus rapidly. This discovery could contribute to the development of new treatments.
Dr. Naglaa Shoukry and Dr. Julie Bruneau, affiliated to both the Research Center of the University of Montreal Hospital Center and the University of Montreal, said that about one-quarter of infected individuals eradicate the infection spontaneously, without treatment.
However, the majority develop persistent infection, a major cause of cirrhosis and cancer of the liver. The only approved treatment for hepatitis C is the antiviral drug pegylated interferon alpha. This drug is successful in only half of cases when administered during chronic infection. Success rates among those treated early after infection are about 90 percent.
In the study, researchers followed a group of intravenous drug users at high risk of hepatitis C infection before and immediately after exposure to hepatitis C. The findings show the importance of early diagnosis and treatment of hepatitis C -- particularly in marginalized populations such as IDUs and aboriginal populations, the researchers said.
Source: United Press International
Related Articles
- Focusing On HIV Treatment Helps Control Concurrent Hepatitis B Infection
- GlobeImmune Announces Presentation of Results From a Randomized Phase 1b Study of the GI-5005 Tarmogen in Patients With Chronic Hepatitis C Infection
- Infections - Helminthic Infestations Drug Pipeline Report Contains Detailed Information on the Current Drug Pipeline
- New Report Examines the Fungal Infections or Candidiasis Drug Pipeline
- The American Liver Foundation Urges Cautious Optimism About CDC Report on Declining Acute Hepatitis Infection Rates
- Treatment for Drug-Resistant HIV Developed
- Drug Researcher MDS Adds Beds in Lincoln
- GlobeImmune Initiates Phase 1b Study of GI-5005 for Chronic Hepatitis C Infection
- Vaccination Tames Hepatitis A Infection
- N.H. Sees Spike in Hepatitis A Infections
User Comments (0)

RSS Feeds